These findings include older age of onset of DM, severe cutaneous disease, resistance to treatment, prior history of malignancy, absence of myositis-specific and myositis-associated antibodies, and the presence of p155/140 and/or anti-NXP2 antibodies [5,9]. Here, MORC3 is linked to dermatomyositis.